| Recruiting | A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In NCT05199688 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® Du NCT05909761 | Amgen | — |
| Not Yet Recruiting | Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder NCT06561009 | Tianjin Medical University General Hospital | Phase 1 / Phase 2 |
| Enrolling By Invitation | Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder NCT06374264 | MedRhythms, Inc. | N/A |
| Recruiting | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinII NCT06474520 | Tongji Hospital | N/A |
| Recruiting | Biomarkers in Autoimmune Disease of Nervous System NCT06502015 | Tongji Hospital | — |
| Recruiting | Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders NCT05891379 | Xuanwu Hospital, Beijing | — |
| Not Yet Recruiting | FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack NCT06497374 | Tianjin Medical University General Hospital | Phase 2 |
| Active Not Recruiting | Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) NCT06180278 | Amgen | Phase 4 |
| Recruiting | Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies NCT05966467 | Alexion Pharmaceuticals, Inc. | — |
| Recruiting | Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder NCT05549258 | Amgen | Phase 2 |
| Completed | Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica NCT05551598 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Phase 2 |
| Active Not Recruiting | Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Sp NCT05403138 | Tianjin Medical University General Hospital | Phase 2 / Phase 3 |
| Unknown | Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinatin NCT05414487 | Tianjin Medical University General Hospital | — |
| Active Not Recruiting | A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) NCT05314010 | Beijing Mabworks Biotech Co., Ltd. | Phase 3 |
| Terminated | A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention NCT05269667 | Hoffmann-La Roche | Phase 4 |
| Recruiting | Ofatumumab in AQP4-IgG Seropositive NMOSD NCT05504694 | Tang-Du Hospital | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD NCT05346354 | Alexion Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Unknown | A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder NCT05284175 | Peking Union Medical College Hospital | N/A |
| Enrolling By Invitation | CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for NCT04886492 | CorEvitas | — |
| Completed | A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum NCT04660539 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the N NCT04561557 | Tongji Hospital | EARLY_Phase 1 |
| Recruiting | Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) NCT05017142 | University of Bern | — |
| Terminated | A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica NCT04155424 | Alexion Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD NCT04201262 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Unknown | Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory N NCT04064944 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Recruiting | French Registry for Monitoring Pregnancies for Multiple Sclerosis NCT03900221 | Hospices Civils de Lyon | — |
| Completed | Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital NCT03819413 | Assiut University | — |
| Withdrawn | Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and C NCT03605238 | Chinese PLA General Hospital | Phase 1 |
| Completed | Central Pain Study for ABX-1431 NCT03138421 | Abide Therapeutics | Phase 1 |
| Completed | Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses NCT02276963 | Johns Hopkins University | Phase 1 |
| Completed | Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder NCT02893111 | Tianjin Medical University General Hospital | Phase 2 |
| Completed | Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients NCT03002038 | Isfahan University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients NCT02003144 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Terminated | A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study) NCT01892345 | Alexion Pharmaceuticals, Inc. | Phase 3 |
| Completed | Rituximab at Low dosE for neuromyelitiS optiCa spectrUm disordEr (RESCUE) NCT04256252 | Tang-Du Hospital | Phase 4 |
| Completed | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations NCT01777412 | Johns Hopkins University | Phase 1 |
| Completed | Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spe NCT01845584 | Nihon Pharmaceutical Co., Ltd | Phase 2 |
| Active Not Recruiting | The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders NCT01623076 | University of Texas Southwestern Medical Center | — |
| Completed | Maintenance Plasma Exchange for Neuromyelitis Optica NCT01500681 | Mayo Clinic | — |